Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests

Posted by & filed under Health Sciences.

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed – but results have been inconclusive at best and at times contradictory. A new study provides an explanation why: Only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

Comments are closed.

Feedback

eSTEM Feedback

We appreciate any and all feedback about our site; praise, ideas, bug reports you name it!

e.g. Indifferent, Undecided, Unconcerned e.g.Kidding, Amused, Silly e.g. Happy, Confident, Grateful e.g. Sad, Dissapointed, Confused, Angry